Literature DB >> 14552830

Pharmacokinetic study of ellagic acid in rat after oral administration of pomegranate leaf extract.

Fan Lei1, Dong-Ming Xing, Lan Xiang, Yu-Nan Zhao, Wei Wang, Lu-Jun Zhang, Li-Jun Du.   

Abstract

Quantification of ellagic acid, the principal bioactive component of pomegranate leaf extract, in rats plasma following oral administration of pomegranate leaf extract was achieved by using a high-performance liquid chromatographic method. The calibration curve for ellagic acid was linear (r2=0.9998) ver the concentration range 0.026-1.3 microg/ml. The intra- and inter-day assays of ellagic acid from rat plasma were less than 6.52% at concentration range from 26 to 1300 ng/ml and good overall recoveries (94.5-102.4%) were found on same concentrations. The concentration-time profile was fitted with an open two-compartment system with lag time and its max concentration of ellagic acid in plasma was 213 ng/ml only 0.55 h after oral administration extract 0.8 g/kg. The pharmacokinetic profile indicates that ellagic acid has poor absorption and rapid elimination after oral administration pomegranate leaf extract, and part of it was absorbed from stomach.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14552830     DOI: 10.1016/s1570-0232(03)00610-x

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  26 in total

Review 1.  Berries: improving human health and healthy aging, and promoting quality life--a review.

Authors:  Octavio Paredes-López; Martha L Cervantes-Ceja; Mónica Vigna-Pérez; Talía Hernández-Pérez
Journal:  Plant Foods Hum Nutr       Date:  2010-09       Impact factor: 3.921

Review 2.  Bioavailability challenges associated with development of anti-cancer phenolics.

Authors:  Song Gao; Ming Hu
Journal:  Mini Rev Med Chem       Date:  2010-06       Impact factor: 3.862

3.  Urolithin A, a Novel Natural Compound to Target PI3K/AKT/mTOR Pathway in Pancreatic Cancer.

Authors:  Tulasigeri M Totiger; Supriya Srinivasan; Venkatakrishna R Jala; Purushottam Lamichhane; Austin R Dosch; Alexander A Gaidarski; Chandrashekhar Joshi; Shobith Rangappa; Jason Castellanos; Praveen Kumar Vemula; Xi Chen; Deukwoo Kwon; Nilesh Kashikar; Michael VanSaun; Nipun B Merchant; Nagaraj S Nagathihalli
Journal:  Mol Cancer Ther       Date:  2018-11-07       Impact factor: 6.261

4.  Pomegranate inhibits neuroinflammation and amyloidogenesis in IL-1β-stimulated SK-N-SH cells.

Authors:  Ravikanth Velagapudi; Gina Baco; Sunjeet Khela; Uchechukwu Okorji; Olumayokun Olajide
Journal:  Eur J Nutr       Date:  2015-07-10       Impact factor: 5.614

5.  Nanoformulated ellagic acid ameliorates pentylenetetrazol-induced experimental epileptic seizures by modulating oxidative stress, inflammatory cytokines and apoptosis in the brains of male mice.

Authors:  Mohamed A El-Missiry; Azza I Othman; Maher A Amer; Mohammed Sedki; Sara M Ali; Ibrahim M El-Sherbiny
Journal:  Metab Brain Dis       Date:  2019-11-14       Impact factor: 3.584

6.  Possible synergistic prostate cancer suppression by anatomically discrete pomegranate fractions.

Authors:  Ephraim P Lansky; Wenguo Jiang; Huanbiao Mo; Lou Bravo; Paul Froom; Weiping Yu; Neil M Harris; Ishak Neeman; Moray J Campbell
Journal:  Invest New Drugs       Date:  2005-01       Impact factor: 3.850

7.  Pomegranate polyphenols and extract inhibit nuclear factor of activated T-cell activity and microglial activation in vitro and in a transgenic mouse model of Alzheimer disease.

Authors:  Lalida Rojanathammanee; Kendra L Puig; Colin K Combs
Journal:  J Nutr       Date:  2013-03-06       Impact factor: 4.798

Review 8.  The Effects of Ellagic Acid upon Brain Cells: A Mechanistic View and Future Directions.

Authors:  Marcos Roberto de Oliveira
Journal:  Neurochem Res       Date:  2016-02-04       Impact factor: 3.996

9.  Ellagic acid ameliorates lung injury after intestinal ischemia-reperfusion.

Authors:  Abdullah Böyük; Akin Onder; Murat Kapan; Metehan Gümüş; Uğur Fιrat; Mustafa Kemal Başaralι; Harun Alp
Journal:  Pharmacogn Mag       Date:  2011-07       Impact factor: 1.085

10.  Bioavailable constituents/metabolites of pomegranate (Punica granatum L) preferentially inhibit COX2 activity ex vivo and IL-1beta-induced PGE2 production in human chondrocytes in vitro.

Authors:  Meenakshi Shukla; Kalpana Gupta; Zafar Rasheed; Khursheed A Khan; Tariq M Haqqi
Journal:  J Inflamm (Lond)       Date:  2008-06-13       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.